The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 08, 2005

Filed:

Jun. 05, 1998
Applicants:

Boris Tabakoff, Elizabeth, IL (US);

Lawrence Snell, Aurora, CO (US);

Paula L. Hoffman, Denver, CO (US);

Inventors:

Boris Tabakoff, Elizabeth, IL (US);

Lawrence Snell, Aurora, CO (US);

Paula L. Hoffman, Denver, CO (US);

Assignee:

Lohocla Research Corporation, Denver, CO (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K031/4706 ; C07D215/42 ; A61P025/08 ; A61P025/22 ;
U.S. Cl.
CPC ...
Abstract

Compounds, composition and method for ameliorating alcohol or drug dependency withdrawal syndromes and withdrawal-induced brain damage are disclosed. In particular, a series of N-substituted-4-uredo-5,7-dihalo-2-carboxy quinoline compounds are disclosed having combined properties as antagonists of voltage-sensitive sodium channels (VSNaC) and as selective competitive antagonists at the strychnine-intensive glycine site of N-methyl-D-aspartate (NMDA) receptors. The disclosed compounds prevent or reduce the signs and symptoms of neurohyperexcitability and particularly the neurohyperexcitability associated with withdrawal syndrome manifested by patients upon withdrawal from chronic use of dependence inducing agents (e.g. ethanol, barbiturates, opiates etc.). The combined actions of the disclosed compound on VSNaC and NMDA receptors also impart properties to these compounds that are important in preventing and reducing excitotoxic neurodegeneration and reducing anxiety without the undesirable CNS depressant side-effects of agents hitherto employed for these purposes.


Find Patent Forward Citations

Loading…